Market Research Assistance

On the Web
Refine Result

By Date

Last Month
Last 3 Months
Last 6 Months
Last Year
Last 2 Years

By Price

< $1000
$1000-$2500
$2501-$4000
$4001-$5500
$5501-$7500
$7501-$9000
>$9000

Diseases & treatment Market Research Reports

Titlepublishedprice

Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... of the Multiple Sclerosis (Central Nervous System) pipeline landscape. Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to......"
30-Nov-2022$2500

Canavan Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... e Canavan Disease (Central Nervous System) pipeline landscape. Canavan disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutati......"
30-Nov-2022$2000

Globoid Cell Leukodystrophy (Krabbe Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... ) - Drugs In Development, 2022, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape. Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder cause......"
30-Nov-2022$2000

Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... of the Huntington Disease (Central Nervous System) pipeline landscape. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent ......"
30-Nov-2022$2500

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... le System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drugs In Development, 2022, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline ......"
30-Nov-2022$2000

Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... 22, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape. Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads t......"
30-Nov-2022$2000

Ornithine-Transcarbamylase Deficiency Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... evelopment, 2022, provides an overview of the Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline landscape. Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by complete or part......"
30-Nov-2022$2000

Gaucher Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... e Gaucher Disease (Genetic Disorders) pipeline landscape. Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung d......"
30-Nov-2022$2000

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... r Syndrome ) - Drugs In Development, 2022, provides an overview of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) pipeline landscape. MPS I (Mucopolysaccharidosis I) is an inherited lysosomal storage disorder ......"
30-Nov-2022$2000

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

By Global Markets Direct
"...... unter Syndrome ) - Drugs In Development, 2022, provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders) pipeline landscape. Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome......"
30-Nov-2022$2000

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy